Trending...
- A rare chance to own a multi-family property in the heart of Bay Ridge
- CORPORATE IMMIGRATION PARTNERS, PC ANNOUNCES ANNE NAKAMURA HAS JOINED THE FIRM
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
YANTAI, China, June 5, 2024 ~ At the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024, RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its latest innovations in the field of global cancer treatment. The company presented major research results on its proprietary antibody drug conjugates (ADCs) Disitamab Vedotin (RC48) and RC88.
The innovative drugs were featured in one Clinical Science Symposium, five Poster presentations, and ten online Abstracts at ASCO 2024. These presentations covered multiple cancer types including gastric and bladder cancer, and gynecological tumors. The studies included both monotherapy and combination therapies.
Dr. Jianmin Fang, CEO of RemeGen, expressed his honor at presenting the company's latest research findings on an internationally renowned stage such as ASCO Annual Meeting 2024. He stated that this not only demonstrates RemeGen's leading position in the field of antibody-drug conjugates in China but also proves their commitment to continuing research efforts to provide effective treatment options for patients worldwide.
More on illi News
One of the highlights of RemeGen's presentations was an oral presentation at a Clinical Science Symposium by Professor Song Li from Qilu Hospital of Shandong University. The presentation was based on a randomized, controlled (RCT) multicenter, single-arm, Phase II trial investigating the efficacy of RemeGen's disitamab vedotin (RC48) combined with toripalimab and the oral fluoropyrimidine S-1 in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.
In addition to this symposium, RemeGen also presented five posters at ASCO 2024. One of these posters, presented by Professor Sheng Xinan from Peking University Cancer Hospital, focused on the preliminary efficacy and safety results of RC48-C017, a Phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC). The interim results showed promising efficacy and a manageable safety profile in operable MIBC patients, supporting further investigation for disitamab vedotin plus toripalimab in this population.
More on illi News
Other poster presentations included a Phase II multi-center study on adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression, and a prospective, single-arm, single-center clinical study on disitamab vedotin combined with toripalimab in patients with advanced penile cancer who have progressed on treatment or are intolerant to cisplatin chemotherapy.
In addition to these presentations, RemeGen also had ten online abstracts accepted by ASCO. These abstracts reflected the results of their RC48 and RC88 drugs in bladder, breast, and GI cancers. This further demonstrates the company's prolific innovation in global cancer treatment.
RemeGen's participation at ASCO 2024 highlights their commitment to advancing cancer treatment options globally. With their innovative drugs and ongoing research efforts, they continue to make significant contributions to the field of oncology.
The innovative drugs were featured in one Clinical Science Symposium, five Poster presentations, and ten online Abstracts at ASCO 2024. These presentations covered multiple cancer types including gastric and bladder cancer, and gynecological tumors. The studies included both monotherapy and combination therapies.
Dr. Jianmin Fang, CEO of RemeGen, expressed his honor at presenting the company's latest research findings on an internationally renowned stage such as ASCO Annual Meeting 2024. He stated that this not only demonstrates RemeGen's leading position in the field of antibody-drug conjugates in China but also proves their commitment to continuing research efforts to provide effective treatment options for patients worldwide.
More on illi News
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- Veterans and Young Job Seekers Get a Boost Through Mentor Agile's Expanded WIOA Support Program
- Build. Repair. Refresh – Summer Pond Projects Are in Full Swing!
- Lake Street Capital Partners Establishes New Residential Services Platform HighPoint Exterior Home Services by Partnering with Choufani & Bailey Roofing & Restoration
- $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
One of the highlights of RemeGen's presentations was an oral presentation at a Clinical Science Symposium by Professor Song Li from Qilu Hospital of Shandong University. The presentation was based on a randomized, controlled (RCT) multicenter, single-arm, Phase II trial investigating the efficacy of RemeGen's disitamab vedotin (RC48) combined with toripalimab and the oral fluoropyrimidine S-1 in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.
In addition to this symposium, RemeGen also presented five posters at ASCO 2024. One of these posters, presented by Professor Sheng Xinan from Peking University Cancer Hospital, focused on the preliminary efficacy and safety results of RC48-C017, a Phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC). The interim results showed promising efficacy and a manageable safety profile in operable MIBC patients, supporting further investigation for disitamab vedotin plus toripalimab in this population.
More on illi News
- Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
- Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
- CarobWay Launches Food-Forward Prebiotic Fiber Innovation at IFT
- Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
Other poster presentations included a Phase II multi-center study on adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression, and a prospective, single-arm, single-center clinical study on disitamab vedotin combined with toripalimab in patients with advanced penile cancer who have progressed on treatment or are intolerant to cisplatin chemotherapy.
In addition to these presentations, RemeGen also had ten online abstracts accepted by ASCO. These abstracts reflected the results of their RC48 and RC88 drugs in bladder, breast, and GI cancers. This further demonstrates the company's prolific innovation in global cancer treatment.
RemeGen's participation at ASCO 2024 highlights their commitment to advancing cancer treatment options globally. With their innovative drugs and ongoing research efforts, they continue to make significant contributions to the field of oncology.
Filed Under: Business
0 Comments
Latest on illi News
- Universal Destinations & Experiences Plans Second Universal Horror Unleashed in Chicago
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Big Green Egg and Ace Hardware Launch "Egg Your Neighbor" Contest to Celebrate Neighborhood Heroes
- Pi9 Becomes a Microsoft Training Services Partner
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
- Suzanne Harp named Managing Director in Texas, USA
- $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
- Emerald Reimagined: Garden Party & Fundraiser to Celebrate Englewood's Bold Next Chapter
- An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
- Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
- Alpha Modus Files 7th IP Action Against Rackspace Following $3M CEO Investment and Strategic Partnership Expansion
- Mortgage Rates And Demand Are Stuck In A Holding Pattern